by According to Precedence Research, during the forecast period of 2022 to 2030, the global anticoagulants market is estimated to develop at a compound annual growth rate (CAGR) of 9.09%. The global anticoagulants market was valued at USD 32 billion in 2021, and it is predicted to exceed USD 70 billion by 2030. The study investigates several elements and their consequences on the growth of the anticoagulants market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1796
This report focuses on anticoagulants market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall anticoagulants market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of anticoagulants, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of anticoagulants has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the anticoagulants market.
Some of the prominent players in the anticoagulants market include:
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company
- Bayer AG
- Boehringer Ingelheim GmbH
- Aspen Holdings
- GlaxoSmithKline Plc
- Pfizer Inc.
- Sanofi S.A.
- Portola Pharmaceuticals
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1796
Segments Covered in the Report
By Indication of disease
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Atrial Fibrillation
- Heart Attacks
- Others
By Administration Route
- Oral
- Injectable
By Drug Class
- NOACs
- Eliquis
- Bevyxxa
- Xarelto
- Savaysa & lixiana
- Pradaxa
- Heparin & LMWH
- Vitamin K Antagonist
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacy
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anticoagulants Market
5.1. COVID-19 Landscape: Anticoagulants Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anticoagulants Market, By Indication of disease
8.1. Anticoagulants Market, by Indication of disease, 2022-2030
8.1.1. Pulmonary Embolism (PE)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Deep Vein Thrombosis (DVT)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Atrial Fibrillation
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Heart Attacks
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anticoagulants Market, By Administration Route
9.1. Anticoagulants Market, by Administration Route e, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Injectable
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anticoagulants Market, By Drug Class
10.1. Anticoagulants Market, by Drug Class, 2022-2030
10.1.1. NOACs
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Heparin & LMWH
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Vitamin K Antagonist
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Anticoagulants Market, By Distribution Channel
11.1. Anticoagulants Market, by Distribution Channel, 2022-2030
11.1.1. Hospitals Pharmacies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Anticoagulants Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Johnson & Johnson
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol-Myers Squibb Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Daiichi Sankyo Company
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bayer AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. BoehringerIngelheim GmbH
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Aspen Holdings
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline Plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Pfizer Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi S.A.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Portola Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1796
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
